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polymorphism of Fc Receptor (FcyRII) Is Reflected in Cytokine 
Release and Adverse Effects of mlgG1 Anti-CD3/TCR Antibody 
During Rejection Treatment After Renal Transplantation
W.J.M. Tax, L.A.M. Frenken, C. A.F.M. Glaudemans, W.P.M. Tamboer, and R.A.P. Koene
A
NTI-CD3 monoclonal antibody (MAb) OKT3 is im­
munosuppressive, bu t  the first injection usually 
evokes severe adverse effects that are related to a massive 
release of cytokines in vivo. The high serum levels of tumor 
necrosis factor (TNF-a), interferon-gamma (IFN-y)} and to 
a lesser extent interleukin-2 (IL-2), that are observed a few 
hours after the first injection, presumably result from T-cell 
activation in vivo.1 Previous studies have demonstrated that 
in vitro T-cell activation and proliferation induced by 
anti-CD3 MAb are dependent on the presence of mono- 
cytes bearing Fey receptors that bind murine IgG. The Fey 
receptor responsible for binding of murine IgG l (mlgGl) is 
FcyRIIa, an isoform of FcyRII that occurs on monocytes, 
macrophages, and granulocytes.2 FcyRIIa is known to be 
polymorphic: m lgG l anti-CD3 MAb induces T-cell prolif­
eration in vitro in only 70% of normal Caucasian individuals 
(“high-responders” [HR]) but not in “low-responder” (LR) 
individuals.3,4 This genetic polymorphism of FcyRII is also 
reflected in the release of cytokines (IFN-y, IL-2) observed 
in vitro when mononuclear cells are incubated with m lgGl 
anti-CD3 MAb.5
We investigated the role of this FcyRII polymorphism in 
the release of cytokines in vivo and the occurrence of 
adverse effects after the administration of WT31, a m lgGl 
MAb directed against the CD3-associated T-cell receptor
(TCR)6’7
PATIENTS AND METHODS
The large-scale production of WT31 was performed at the Dutch 
National Institute of Public Health and Environmental Protection 
as described elsewhere.8
We measured the T-cell proliferation in vitro induced by WT31 
to determine whether patients to be treated with WT31 were HR 
or LR.3
WT31 was administered by intravenous infusion, after informed 
consent, to nine patients with a rejection episode after kidney 
transplantation. The diagnosis of rejection was confirmed by his­
tology of allograft biopsy (except in one case in which no biopsy 
could be taken). Four patients were HR, and live were LR.
Blood samples were collected in EDTA tubes at regular intervals 
after the start of the first administration of WT31. Plasma was 
obtained by immediate centrifugation at 4DC, and aliquots were 
stored at -70°C until tested. An immunoradiometric assay 
(IRMA) was used to measure TNF-a, IFN-y, IL-fi, and IL-2 
(Medgenix Diagnostics, FJeurus, Belgium).
RESULTS AND DISCUSSION
This pilot study was set up primarily to investigate whether 
or not the anti-TCR antibody WT31 induces the release of
cytokines in vivo and the cytokine-associated ufirst-dose 
reaction” usually observed with anti-CD3 antibodies. Fur­
thermore, in case these phenomena occurred, we wanted to 
find out if their occurrence was related to the known 
polymorphism of FcyRII, the human Fc receptor that can 
bind mlgGl.
Administration of WT31 (6 mg) to the first H R  patient 
induced a typical “first-dose reaction.” In plasma samples 
obtained from this patient during the first hours after the 
start of WT31, very high concentrations of circulating 
cytokines were measured (eg, a peak value of 1750 pg/mL 
for TNF-a), In addition to the cytokine-related adverse 
effects, we observed a marked decrease in the number of 
peripheral lymphocytes and, surprisingly, a profound gran­
ulocytopenia which necessitated the interruption of WT31 
treatment for several days. In view of the side effects 
obseived in this patient, the other H R  patients received a 
much lower initial dose (1 mg) of WT31, and 50 mg of 
intravenous prednisolone 1 hour before WT31 administra­
tion. Despite this, all HR patients except one had a 
first-dose reaction and granulocytopenia (although to a 
lesser extent than the first HR patient). One H R  patient 
had some symptoms of cytokine-related syndrome, but only 
the day after the start of WT31 and not immediately 
following it. In complete contrast, none of the five LR 
patients showed any sign of first-dose reaction (or granulo­
cytopenia), despite the fact that the first dose of WT31 was
6 mg and four of them received no premedication with 
prednisolone. An increase of T N Fa was measured in 
plasma samples from all H R  patients but not in the three 
LR patients analyzed until now. No increase of IFN-y or 
IL-6 was observed in the LR patients, whereas increased 
concentrations were measured in all HR patients except the 
one who showed no immediate first-dose response. The 
serological and clinical findings in HR and LR patients are 
summarized in Table 1.
It is remarkable that one of the HR patients .showed no 
immediate side effects of WT31 administration, despite an
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Table 1. Cytokine Release and “First-Dose Reaction” 
Following the First Administration of WT31 to HR and LR
Patients
HR LR
Increase of TNFa 4/4 0/3
Increase of IFNy 3/4 0/3
Increase of IL-6 3/4 0/3
First-dose reaction 3/4* 0/5
G ranulocytopenia 3/4 0/5
‘Adverse effects including fever and myalgia were also observed in the fourth 
H R  patient, but only on the second day of treatment.
increase of plasma TNF-a. In this patient there was no 
increased IFN -7  or IL-6. These findings are reminiscent of 
those obtained by Chatenoud and coworkers, who observed 
only mild or no side effects after administration of BMA031 
(a mIgG2b anti-TCR MAb), despite a sharp increase of 
isolated T N F -a  (in the absence of IFN-y).9 Apparently, 
IFN-y is required to induce the characteristic “first-dose 
reaction,” This hypothesis is supported by the protective 
effect of anti-IFN-y antibodies on anti-CD3-induced mor­
bidity and mortality in mice,10
We have recently reviewed the clinical significance of the 
polymorphism of human Fc receptors for immunothera­
py.11,12 Our current data indicate that WT31 can induce 
cytokine release in vivo and the cytokine-associated syn­
drome, and that the polymorphism of human FcyRII 
determines whether or not this will occur. Furthermore, 
W T3I induced granulocytopenia in three of the four H R  
patients, but in none of the LR patients. This granulocyto­
penia might be related to the expression of Fcyll on 
granulocytes. These findings imply that the HR/LR poly­
morphism defined by in vitro experiments indeed has direct 
implications for the in vivo use of mlgGl MAb. Previously 
published data obtained from a small group of patients 
treated with a mlgGl anti~CD8 antibody already suggested 
that elimination of CD8-positive cells only occurred in H R
patients.13 Knowledge obtained from such pilot studies  
performed with mouse MAb may be helpful in des igning  
suitably modified antibodies for optimal efficacy and mini­
mal toxicity.14
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